When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
IPSEF - Exelixis and Ipsen initiate COSMIC-312 trial in advanced HCC
Ipsen Sa Ord
Exelixis (NASDAQ:EXEL) and Ipsen (OTCPK:IPSEF) has initiated COSMIC-312, a phase 3 pivotal trial of cabozantinib (CABOMETYX) in combination with atezolizumab (TECENTRIQ) versus sorafenib in previously untreated advanced hepatocellular carcinoma (HCC).
More news on: Exelixis, Inc., Ipsen S.A., Ipsen S.A. ADR, Healthcare stocks news,